GAINESVILLE, Fla., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, announced that company management will be presenting at upcoming scientific and investor conferences.
Stifel 2014 Healthcare Conference
- Sue Washer, President and CEO, will present at the Stifel 2014 Healthcare Conference taking place on Tuesday, November 18th, 2014 at 3:35pm ET in New York. To access a live webcast of this presentation, please visit http://ir.agtc.com/. A replay will be available for two weeks following the presentation.
3rd Annual Cell Culture & Bioprocessing Congress
- David R. Knop, Senior Director, Process Development will present at the 3rd Annual Cell Culture & Bioprocessing Congress in London on November 17th, 2014 at 9:00am GMT. Dr. Knop's presentation, titled, "Production of AAV-based Phase 2 Human Clinical Trial Material by HAVE," will be part of the congress' Biological Production stream and will include an overview of AGTC's pipeline and manufacturing processes, as well as a discussion of the company's current phase 2a and 2b trials for its lead product candidates.
About AGTC
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology. AGTC's lead product candidates focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye, caused by mutations in single genes, that significantly affect visual function and currently lack effective medical treatments. AGTC has recently begun development of a product to treat Wet AMD using the company's experience in ophthalmology to expand into disease indications with larger markets.